Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Springfield, IL
NPI: 1235128109Primary Practice Location
MEMORIAL MEDICAL CENTER
701 N 1st St, Springfield, IL
Primary Employer
SIU Healthcare
siumed.org
HQ Phone
Get M.D. Krishna's Phone Numberphone_androidMobile
Get M.D. Krishna's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 101 | 132 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 79 | 112 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 54 | 131 |
| 4 | 99212Established patient outpatient visit, total time 10-19 minutes | 39 | 57 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 35 | 65 |
Characterization of immortalized human mammary epithelial cell line HMEC 2.6.
Authors: Joshi, Pooja S, Modur, Vishnu, Cheng, JiMing, Robinson, Kathy, Rao, Krishna
Journal: Tumour Biol
Authors: Rao, Krishna, Bryant, Eileen, O'Hara Larivee, Siobhan, McDougall, James K
Journal: Cancer Lett
Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer.
Authors: Sherjeel Sana
Publication Date: 2019-07-20
Lead Sponsor: Calithera Biosciences, Inc
Intervention / Treatment: DRUG: Placebo, DRUG: everolimus, DRUG: CB-839
Lead Sponsor: Exact Sciences Corporation
Intervention / Treatment: OTHER: Blood Sample Collection
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, DRUG: Cabozantinib S-malate
